BackWelgene Biotech ,Ltd. Overview

Welgene Biotech ,Ltd. Long Term Debt

Latest long-term debt for 6661.TWO: $220M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$220.11M
↑ 96.05% YoYΔ $107.84M vs prior year quarter

Peer trimmed avg / median

Loading

Welgene Biotech ,Ltd. Long Term Debt History

Loading

Welgene Biotech ,Ltd. vs. peers: Long Term Debt Comparison

Loading

Welgene Biotech ,Ltd. Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Welgene Biotech ,Ltd. (6661.TWO) FAQ

Welgene Biotech ,Ltd. posts a long-term debt of $220M as of June 2026. That compares with $110M in the prior-year period — up 96.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Welgene Biotech ,Ltd.'s long-term debt was $110M. The latest reading is $220M — a 96.0% year-over-year increase (period ending June 2026). Use the history and growth charts on this page for a longer lookback.

Long-Term Debt is one piece of Welgene Biotech ,Ltd.'s financial statement story. At $220M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for 6661.TWO's long-term debt usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Welgene Biotech ,Ltd.'s other metric pages and overview cover the third.